LSG1

Across TCGA pan-cancer cohorts, LSG1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LSG1 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LSG1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LSG1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where LSG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.357	0.935	<.001	66	view →
PDAC	OS	Median	II,III,IV	0.456	0.600	.016	17	view →
UCEC	DFS	Median	III,IV	0.904	0.445	.037	4	view →
LSCC	DFS	Median	II,III,IV	0.873	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LSG1–CCRCC (OS)

Open the CCRCC breakdown →